Search | Boehringer Ingelheim US
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
News
May 02, 2024
[Clinical Trials](/content/us/science-innovation/human-health-innovation/clinical-studies/clinical-trials "Clinical Trials"/index.html)
Clinical Trials
Find out more on why Boehringer Ingelheim's range of clinical trials are an essential aspect of new medicine development.
Science & Innovation
Stories
[Confronting health disparities in clinical trials](/content/us/human-health/cancer/confronting-health-disparities-clinical-trials "Confronting health disparities in clinical trials"/index.html)
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Human Health
Stories
[Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers](/content/us/media/press-releases/boehringer-ingelheim-advances-novel-bi-specific-trailr2-cdh17-antibody-phase-1-clinical-trial "Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers"/index.html)
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
BI announces the advancement of the tetravalent therapeutic antibody, BI 905711, to its first-in-human clinical trial for patients with advanced GI cancers.
News
September 10, 2020
[Clinical Studies](/content/us/science-innovation/human-health-innovation/clinical-studies "Clinical Studies"/index.html)
Clinical Studies
BI's clinical trials are an essential part of the development of new medicines, being the translation of our expertise into breakthrough therapies.
Science & Innovation
Other
[Expanded Access Programs](/content/us/science-innovation/human-health-innovation/clinical-studies/expanded-access-programs "Expanded Access Programs"/index.html)
Expanded Access Programs
Expanded Access Programs
Science & Innovation
Other
[Clinical trials deliver medical breakthroughs – but how do they happen?](/content/us/careers/explore-our-company/clinical-trials-deliver-medical-breakthroughs-how-do-they-happen "Clinical trials deliver medical breakthroughs – but how do they happen?"/index.html)
Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Careers
Stories
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
Read more about the FDA approval of SYNJARDY, based on multiple clinical trials proving the reductions of blood sugar levels in adults with T2D.
News
August 27, 2015
[First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US](/content/us/media/press-releases/first-trials-empagliflozin-chronic-heart-failure-boehringer-ingelheim-us "First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US"/index.html)
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
News
March 17, 2017
[Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction](/content/us/media/press-releases/boehringer-ingelheim-and-lilly-collaborate-duke-clinical-research-institute-pragmatic-trial "Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction"/index.html)
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Read more on how the trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor.
News
May 26, 2020